Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi

AbbVie just scored another win in its campaign to make Skyrizi one of the top blockbusters in the portfolio while pushing the Big Pharma to the top of the industry list of money makers as their cash cow Humira faces biosimilar competition in January.